Akron, Octapharma ink deal to make human AB serum

By The Science Advisory Board staff writers

January 20, 2021 -- Akron Biotech and Octapharma have signed an exclusive agreement to produce virally inactivated human AB serum to bring it to the cell therapy market.

Akron will produce human AB serum converted from Octapharma's pooled solvent/detergent treated human plasma product. Together, they aim to enhance the safety of human serum from viruses, such as SARS-CoV-2.

The products will be colabeled and available in the U.S., E.U., and Asia.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.